The results showed that in the HBeAg-positive cohorts, HBsAg or HBeAg in tandem with ALT was excellent in both defining HBeAg-positive ‘minimal necro-inflammation and non-extensive fibrosis (Grade ≤G1 and Stage ≤S2) and excluding HBeAg-positive extensive fibrosis (Stage ≥S3) and cirrhosis (Stage ≥S4); however, in the HBeAg-negative cohorts, HBV DNA in tandem with ALT was good in both defining HBeAg-negative ‘minimal necro-inflammation and non-extensive fibrosis’ and excluding HBeAg-negative extensive fibrosis and cirrhosis. The gene discussed is GPT; the disease is Cirrhosis.